EPCAM_RAT Epcam ELISA tesk kit
- Known as:
- EPCAM_RAT Epcam Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen16502
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- EPCAM_RAT Epcam ELISA tesk kit
Related genes to: EPCAM_RAT Epcam ELISA tesk kit
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: EPCAM_RAT Epcam ELISA tesk kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Sizeα - Calcitonin Gene Related Peptide, α - CGRP, rat'F 4_80 Antigen (mouse) Host Rat'F 4_80 Antigen (mouse) Host Rat(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit Related articles to: EPCAM_RAT Epcam ELISA tesk kit
- We have previously shown that a T cell engaging bispecific humanized anti-human EpCAM-CD3 antibody efficiently kills a human EpCAM positive human xenograft in an NSG partially humanized mouse injected intravenously with human T cells when the anti-EpCAM-CD3 was delivered intratumorally as an mRNA-LNP. To extend these results we tested the effects of combining the anti-human EpCAM-CD3 with various cytokines injected into a tumor on the left side of NSG mice and an uninjected tumor on the right side of the mice. Combining both IL-12 and GM-CSF with anti-EpCAM-CD3 increased the number of T cells and the expression of genes and pathways that mediated T cell-based killing in the neighborhood of both the injected and the uninjected tumor and substantial increases in the expression of HLA Class II and associated genes in both tumors. This turned the cancer cells into potentially antigen-presenting cells. The effect of combining intratumoral injection of anti-EpCAM-CD3 with cytokines IL-12 and GM-CSF on tumor growth distal to the injection site avoids serious side effects on normal tissue, and suggests this technology offers a major approach to immunotherapy for treatment of a wide range of cancers from early to severe late stages. - Source: PubMed
Publication date: 2026/09/04
Golubovskaya VitaHu LiangZhang ShimingSienkiewicz JohnZhou HuaBerahovich RobertSun JinyingLi LeBodmer WalterWu Lijun - Chronic rhinosinusitis with nasal polyps (CRSwNP) features marked infiltration of diverse inflammatory cells. Cadherin-26 (CDH26) is an adhesion molecule associated with eosinophilic inflammation, but its role in CRSwNP remains undefined. - Source: PubMed
Publication date: 2026/09/03
Zhang QinqinWang XiangdongHe TingZhang YuanZhuang MengyanSu JunMingYu XiaoruLi YingBachert ClausZhang LuoJiao Jian - Therapeutic interventions for posterior segment ocular diseases, including neovascular age-related macular degeneration (nAMD), remain constrained by poor intraocular bioavailability and the need for repeated intravitreal injections. Here, we introduce a noninvasive therapeutic strategy based on stereospecific peptide-polysaccharide conjugates (PPC) for efficient nAMD treatment. A controllable synthetic strategy was established to generate stereospecific L-PPC and D-PPC, among which D-PPC displayed pronounced chirality-dependent bioactivity, characterized by high-affinity binding to integrin receptors and enhanced inhibition of endothelial/epithelial cell proliferation and migration. Following topical administration, D-PPC efficiently overcame ocular barriers and penetrated choroidal lesions while markedly suppressing pathological angiogenesis in a laser-induced choroidal neovascularization mouse model, comparable to that of intravitreal ranibizumab. We elucidated that stereospecific D-PPC modulates key molecular programs in vivo, including T-cell receptor signaling and cell adhesion molecule pathways. Notably, D-PPC exhibited no detectable ocular or systemic toxicity. This study establishes chirality-engineered peptide-polysaccharide conjugates as a noninvasive and effective therapeutic for posterior ocular diseases, providing a structural and mechanistic blueprint for future translational ophthalmic applications. - Source: PubMed
Li YachaoLi BingyanZou DongzheZeng ZenanGuo BeilingGong WenshengDeng KefurongWang ZicongZhou HaixiangZhou YediXu Xianghui - The major birch pollen allergen Bet v 1 primarily affects the nose and eyes of allergic patients. After crossing the epithelial barrier, it causes IgE-mediated effector cell release, triggering inflammatory responses. We sought to develop bispecific nanobodies that bind Bet v 1 on mucosal surfaces to prevent allergen penetration and subsequent activation of effector cells. Intercellular adhesion molecule 1 (ICAM-1), highly upregulated on epithelial cells of allergic individuals, was chosen as an anchor. - Source: PubMed
Publication date: 2026/08/17
Zettl InesEllinger IsabellaZghaebi MohammedJance SarahIzewski VanessaDrescher AnjaBreiteneder HeimoRöck ManuelTollinger MartinEckl-Dorna JuliaTillib Sergei VFlicker Sabine - The profound phenotypic heterogeneity of circulating tumor cells (CTCs) presents a major analytical challenge, demanding technologies capable of high-plex, quantitative single-cell profiling. Here, we introduce PRISM (Phenotypic Resolution via Immuno-SERS Mapping), a biosensing platform engineered to meet this challenge. The platform integrates a high-efficiency dual-antibody (anti-EpCAM/anti-CSV) capture substrate with a suite of seven spectrally orthogonal SERS nanoprobes, enabling crosstalk-free, multiplexed quantification of epithelial, mesenchymal, and stem-like (E-M-S) markers. We demonstrate the platform's robust analytical performance, including high capture efficiency for heterogeneous cell lines and excellent linearity. Its superior phenotypic resolving power was validated by quantitatively distinguishing canonical cell line archetypes and tracking dynamic protein expression shifts during induced epithelial-mesenchymal transition. Applying PRISM to CTCs from pancreatic cancer patients, we introduce a novel data analysis framework, including a 'Metastasis Potential Score' (MPS), to translate high-dimensional spectral data into a clinically relevant metric for risk stratification. Furthermore, longitudinal analysis of patient samples demonstrates the platform's utility as a dynamic monitoring tool, capable of tracking therapy-induced phenotypic shifts. PRISM establishes a powerful analytical methodology for high-dimensional single-cell analysis, providing a robust tool for both fundamental cancer biology research and translational clinical applications. - Source: PubMed
Publication date: 2026/08/26
Wen YanrongLiu MengxiangLiu ChunhuiLin FenxiaLi HuijunCheng HaoHe JianZheng Zuguo